Prostate MRI at Windsong Could Provide Answers That Men and Their Doctors are Searching For in Detecting Prostate Cancer
Windsong has recently added a new solution that helps urologists and oncologists better visualize suspected prostate cancer using MRI technology.
One in six men will be diagnosed with prostate cancer during his lifetime, and it is the most common cancer, other than skin cancer in American men. Prostate cancer is also the second leading cause of cancer death in men behind lung cancer.
Windsong is the only imaging facility in Upstate New York that can offer a comprehensive solution for those patients that have had negative TRUS (trans rectal ultrasound) biopsies, and have elevated and/or rising PSA levels. This new technique incorporates the high resolution of Windsong’s 3T MRI images offering increased sensitivity and improved accuracy in localizing prostate cancer.
The typical male patient may have been to his primary care provider who has been watching an elevating PSA level, and has decided to refer the patient to a urologist. The urologist will then perform the TRUS procedure where up to 14 core samples from the gland are taken. They are sent to a pathologist, and the results may come back negative. The patient and his doctors will then go through the ‘active surveillance’ period until the next PSA level is taken. The next PSA level is still elevated and rising, and another TRUS biopsy could be performed.
Now the patient has another alternative that is a more targeted approach with 3T MRI at Windsong. “Prostate MRI has revolutionized how we diagnose prostate cancer. It enables us to find disease earlier than today’s conventional tests.” according to Raja Cheruvu, MD, Windsong radiologist. For more information call 716.631.2500 to find out more about Prostate MRI at Windsong.
Indications for Diagnostic Prostate MRI:
- Patients with an elevated PSA (Prostate Specific Antigen) level > 4 or abnormally high PSA; and/or a rising PSA level.
- Negative prior TRUS (Trans Rectal Ultra Sound) guided biopsy with continued elevation or rising PSA
- Positive DRE with negative TRUS-guided biopsy
- Preoperative/treatment planning
- Active surveillance after prostectomy, radiation, or hormonal therapy for prostate cancer.